Latest News About Andes Virus

Here’s the latest publicly reported information on Andes virus as of now.

• What Andes virus is and why it matters: Andes virus is a hantavirus circulating mainly in South America, notable for occasionally causing person-to-person transmission in addition to rodent-to-human spillover. Fatality rates in hantavirus infections can be high, and Andes virus has been a focus of vaccine and countermeasure research.[3][5]

• Recent research highlights:

  • In 2024, UTMB researchers reported successful preclinical results for mRNA vaccine candidates against Andes virus in animal models, showing protective efficacy in a lethal-challenge context. This work was published by UTMB scientists and described as encouraging for future vaccine development.[1][2]
  • Related scientific literature continues to document Andes virus genetic diversity, historical outbreaks (including Argentina in 2019–2020), and the broader hantavirus landscape, with peer-reviewed reports detailing human cases, outbreaks, and virology characterizations.[7][8][3]

• Public health resources and context:

  • The CDC maintains fact sheets and clinical guidance about Andes virus and hantaviruses, including transmission routes, clinical features, and prevention considerations, useful for clinicians and public health workers.[5]
  • Reviews and case reports in medical journals provide context on the severity of Andes virus infections and the history of person-to-person transmission events observed in Argentina and Bolivia.[8][7]

• Notable caveats:

  • There is no approved vaccine for Andes virus for humans yet; the UTMB findings represent preclinical progress, not a licensed product at this time.[2][1]
  • Information on outbreaks or new confirmed human cases can emerge rapidly; for the most current status, refer to updates from public health agencies and major journals.

Illustration: A simplified view of the current landscape

• Andes virus biology: rodent-borne hantavirus with occasional human-to-human transmission in certain outbreaks.[5]
• Vaccine progress: preclinical mRNA vaccine candidates showing protection in animal models, ongoing for translational development.[1][2]
• Public health context: ongoing surveillance, case reports, and guidance from CDC and other authorities.[5]

If you’d like, I can narrow to:

• A timeline of Andes virus outbreaks in the Americas,
• A quick summary of the UTMB vaccine study design and key findings, or
• The latest CDC guidance and clinical signs to watch for in potential exposures.